Nucleus accumbens dopaminergic medication of fixed interval schedule- controlled behavior and its modulation by low-level lead exposure

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 2, 1998, Pages 794-805

  Cory Slechta, D A ^a,b   O'Mara, D J ^a   Brockel, B J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHOXY 1(2H) QUINOLINECARBOXYLIC ACID ETHYL ESTER; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; LEAD;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOPAMINE BRAIN LEVEL; DRUG EFFECT; ENVIRONMENTAL EXPOSURE; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; REINFORCEMENT;

ANIMALS; CONDITIONING, OPERANT; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; LEAD; MALE; MICROINJECTIONS; NUCLEUS ACCUMBENS; QUINOLINES; RATS; REINFORCEMENT SCHEDULE; TIME FACTORS;

EID: 0032428351     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bevins RA, Klebaur JE and Bardo MT (1997) Individual differences in response to novelty, amphetamine-induced activity and drug discrimination in rats. Behav Pharmacol 8:113-123.
2. Branch MN and Gollub LR (1974) A detailed analysis of the effects of d-amphetamine on behavior under fixed-interval schedules. J Exp Anal Behav 21:519-539.
3. Brody DJ, Pirkle JL, Kramer RA, Flegal KM, Matte TD, Gunter EW and Paschal DC (1994) Blood lead levels in the US population: Phase I of the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1991). JAMA 272:277-283.
4. Centers for Disease Control (1991) Preventing Lead Poisoning in Young Children: A Statement by the Centers for Disease Control. Centers for Disease Control, Atlanta.
5. Cory-Slechta DA (1994) Neurotoxicant-induced changes in schedule-controlled behavior. In Principles of Neurotoxicology, ed. by LW Chang, pp 313-344, Marcel Dekker, New York.
6. 1 agonist SKF82958. J Neurochem 68:2012-2023.
7. Cory-Slechta DA, Pazmino R and Bare C (1997b) The critical role of the nucleus accumbens dopamine systems in the mediation of fixed interval schedule-controlled operant behavior. Brain Res 764:253-256.
8. Cory-Slechta DA, Pokora MJ and Preston RA (1996) The effects of dopamine agonists on fixed interval schedule-controlled behavior are selectively altered by low level lead exposure. Neurotoxicol Teratol 18:565-575.
9. Cory-Slechta DA, Weiss B and Cox C (1985) Performance and exposure indices of rats exposed to low concentrations of lead. Toxicol Appl Pharmacol 78:291-299.
10. Crawford CA, McDougall SA and Bardo MT (1994) Ontogenic effects of EEDQ on amphetamine-induced behaviors of rats: Role of presynaptic processes. Psychopharmacol 116:152-160.
11. Crawford CA, McDougall SA, Rowlett JK and Bardo MT (1992) Depletion of dopamine binding sites and changes in dopamine and dihydroxyphenylacetic acid levels in 17- and 90-day-old rat striatum after irreversible receptor antagonism. Neurosc Lett 137:265-269.
12. Ferster CB and Skinner BF (1957) Schedules of Reinforcement. Prentice-Hall, Englewood Cliffs, NJ.
13. Fukuchi I, Fujita N, Nakahiro M, Saito K and Yoshida H (1986) D-2 dopamine receptors: Synthesis and turnover in rat striatum. Eur J Pharmacol 127:291-294.
14. Giorgi O and Biggio G (1990a) Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: Turning behavior elicited by D2 dopamine receptor agonists. Brain Res 533:53-59.
15. Giorgi O and Biggio G (1990b) Unilateral inactivation of dopamine receptors after intrastriatal injection of N-ethoxy-carbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): A novel rotational model to investigate dopamine receptor interactions. Pharmacol Biochem Behav 35:877-884.
16. Giorgi O, Pibiri MG, DalToso R and Ragatzu G (1992) Age-related changes in the turnover rates of D1-dopamine receptors in the retina and in distinct areas of the rat brain. Brain Res 569:323-329.
17. Gozlan H, Laporte A-M, Thibault S, Schechter LE, Bolanos F and Hamon M (1994) Differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on various 5-HT receptor binding sites in the rat brain. Neuropharmacology 33:423-431.
18. Hamblin MW and Creese I (1983) Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Life Sci 32:2247-2255.
19. Kelleher RW and Morse WH (1968) Determinants of the behavioral effects of drugs, in Importance of Fundamental Principles of Drug Evaluation, ed. by DH Tedeschi and RE Tedeschi, pp 383-405, Raven Press, New York.
20. Kula NS, George T and Baldessarini RJ (1992) Rate of recovery of D1 and D2 dopaminergic receptors in young vs. adult rat striatal tissue following alkylation with ethoxycarbonyl-ethoxy-dihydroquinoline (EEDQ). Dev Brain Res 66:286-289.
21. McAuley F and Leslie JC (1986) Molecular analyses of the effects of d-amphetamine on fixed-interval schedule performance of rats. J Exp Anal Behav 45:207-219.
22. 3H]CNQX) binding in response to chronic low-level lead exposure: Reversal versus potentiation by chronic dopamine agonist treatment. J Neurochem 69:2466-2476.
23. 1A receptor-mediated hypothermia in mice: Absence of spare receptors and rapid induction of tolerance. Pharmacol Biochem Behav 43:405-411.
24. Morrell G and Giridhar G (1976) Rapid micromethod for blood lead analysis by anodic stripping voltammetry. Clin Chem 22:221-223.
25. Nowak G, Amt J and Hyttel J (1988) EEDQ, a tool for ex vivo measurement of occupancy of D-1 and D-2 dopamine receptors. Eur J Pharmacol 153:309-311.
26. Pellegrino LJ, Pellegrino As and Cushman AJ (1979) A Stereotaxic Atlas of the Rat Brain, 2nd ed. Plenum Press, New York.
27. Piazza PV, Deminiere J-M, LeMoal M and Simon H (1989) Factors that predict individual vulnerability to amphetamine self-administration. Science 245:1511-1513.
28. Pokora MJ, Richfield EK and Cory-Slechta DA (1996) Preferential vulnerability of nucleus accumbens dopamine binding sites to low-level lead exposure: Time course of effects and interactions with chronic dopamine agonist treatments. J Neurochem 67:1540-1550.
29. Robbins TW, Roberts DCS and Koob GF (1983) Effects of d-amphetamine and apomorphine upon operant behavior and schedule-induced licking in rats with 6-hydroxydopamine-induced lesions of the nucleus accumbens. J Pharmacol Exp Ther 224:662-673.
30. Scharding NN and Oehme FW (1973) The use of animal models for comparative studies of lead poisoning. Clin Toxicol 6:419-424.
31. Schoenfeld RI and Seiden LS (1969) Effects of a-methyltryosine on operant behavior and brain catecholamine levels. J Pharmacol Exp Ther 167:319-327.
32. Sills TL, Baird JP and Vaccarino FJ (1993) Individual differences in the feeding effects of amphetamine: Role of nucleus accumbens dopamine and circadian factors. Psychopharmacology 112:211-218.
33. Urbain C, Poling A, Millam J and Thompson T (1978) d-Amphetamine and fixed-interval performance: Effects of operant history. J Exp Anal Behav 29:385-392.
34. Winder C, Garten LL and Lewis PD (1983) The morphological effects of lead on the developing central nervous system. Neuropathol Appl Neurobiol 9:87-108.
35. Zuccarelli RR and Barrett JE (1980) A comparison of the effects of d-amphetamine, cocaine, imipramine and pentobarbital on local and overall rates of responding maintained under a four-component multiple fixed-interval schedule. Pharmacol Biochem Behav 12:899-907.
36. Zuch CL, O Mara DJ and Cory-Slechta DA (1998) Low-level lead exposure selectively enhances dopamine overflow in nucleus accumbens: An in vivo electrochemistry time course study. Toxicol Appl Pharmacol 150:174-185.